Bitcoin halving
What does that mean?
$2.79T
Total marketcap
$142.75B
Total volume
BTC 49.84%     ETH 15.42%
Dominance

Ligand Pharmaceuticals Incorporated LGND Stock

71.27 USD {{ price }} 3.831581% {{change_pct}}%
Exchange
NasdaqGM
Market Cap
1.26B USD
LOW - HIGH [24H]
68.8 - 71.85 USD
VOLUME [24H]
186.01K USD
{{ volume }}
P/E Ratio
23.52
Earnings per share
3.03 USD

Ligand Pharmaceuticals Incorporated Price Chart

Ligand Pharmaceuticals Incorporated LGND Financial and Trading Overview

Ligand Pharmaceuticals Incorporated stock price 71.27 USD
Previous Close 78 USD
Open 77.82 USD
Bid 0 USD x 800
Ask 0 USD x 800
Day's Range 76.16 - 79.66 USD
52 Week Range 47.79 - 85.7 USD
Volume 120.47K USD
Avg. Volume 104.57K USD
Market Cap 1.36B USD
Beta (5Y Monthly) 0.970422
PE Ratio (TTM) 26.959044
EPS (TTM) 3.03 USD
Forward Dividend & Yield N/A (N/A)
Ex-Dividend Date July 2, 2010
1y Target Est 114.33 USD

LGND Valuation Measures

Enterprise Value 1.15B USD
Trailing P/E 26.959044
Forward P/E 18.412586
PEG Ratio (5 yr expected) 0.71
Price/Sales (ttm) 6.6976
Price/Book (mrq) 2.094059
Enterprise Value/Revenue 5.661
Enterprise Value/EBITDA 18.615

Trading Information

Ligand Pharmaceuticals Incorporated Stock Price History

Beta (5Y Monthly) 0.970422
52-Week Change 63.10%
S&P500 52-Week Change 20.43%
52 Week High 85.7 USD
52 Week Low 47.79 USD
50-Day Moving Average 75.35 USD
200-Day Moving Average 68.42 USD

LGND Share Statistics

Avg. Volume (3 month) 104.57K USD
Avg. Daily Volume (10-Days) 107.72K USD
Shares Outstanding 17.27M
Float 16.39M
Short Ratio 8.64
% Held by Insiders 5.66%
% Held by Institutions 88.91%
Shares Short 827.08K
Short % of Float 7.07%
Short % of Shares Outstanding 4.79%

Dividends & Splits

Trailing Annual Dividend Rate 0
Trailing Annual Dividend Yield 0%
5 Year Average Dividend Yield N/A
Payout Ratio 0
Last Split Factor 1603:1000

Financial Highlights

Fiscal Year

Fiscal Year Ends December 31, 2022
Most Recent Quarter (mrq) March 31, 2023
Next Fiscal Year End December 31, 2023

Profitability

Profit Margin 11.76%
Operating Margin (ttm) 7.41%
Gross Margin 58.07%
EBITDA Margin 30.41%

Management Effectiveness

Return on Assets (ttm) 0.98%
Return on Equity (ttm) 7.13%

Income Statement

Revenue (ttm) 203.71M USD
Revenue Per Share (ttm) 12.03 USD
Quarterly Revenue Growth (yoy) 20.39%
Gross Profit (ttm) 107.34M USD
EBITDA 61.96M USD
Net Income Avi to Common (ttm) 51.32M USD
Diluted EPS (ttm) 2.93
Quarterly Earnings Growth (yoy) N/A

Balance Sheet

Total Cash (mrq) 282.66M USD
Total Cash Per Share (mrq) 16.37 USD
Total Debt (mrq) 88.68M USD
Total Debt/Equity (mrq) 13.72 USD
Current Ratio (mrq) 3.317
Book Value Per Share (mrq) 37.721

Cash Flow Statement

Operating Cash Flow (ttm) 119.79M USD
Levered Free Cash Flow (ttm) 102.25M USD

Profile of Ligand Pharmaceuticals Incorporated

Country United States
State CA
City San Diego
Address 3911 Sorrento Valley Boulevard
ZIP 92121
Phone 858 550 7500
Website https://www.ligand.com
Industry Biotechnology
Sector(s) Healthcare
Full Time Employees 76

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in San Diego, California.

Q&A For Ligand Pharmaceuticals Incorporated Stock

What is a current LGND stock price?

Ligand Pharmaceuticals Incorporated LGND stock price today per share is 71.27 USD.

How to purchase Ligand Pharmaceuticals Incorporated stock?

You can buy LGND shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.

What is the ticker symbol for Ligand Pharmaceuticals Incorporated?

The stock symbol or ticker of Ligand Pharmaceuticals Incorporated is LGND.

Which industry does the Ligand Pharmaceuticals Incorporated company belong to?

The Ligand Pharmaceuticals Incorporated industry is Biotechnology.

How many shares does Ligand Pharmaceuticals Incorporated have in circulation?

The max supply of Ligand Pharmaceuticals Incorporated shares is 17.71M.

What is Ligand Pharmaceuticals Incorporated Price to Earnings Ratio (PE Ratio)?

Ligand Pharmaceuticals Incorporated PE Ratio is 23.52145200 now.

What was Ligand Pharmaceuticals Incorporated earnings per share over the trailing 12 months (TTM)?

Ligand Pharmaceuticals Incorporated EPS is 3.03 USD over the trailing 12 months.

Which sector does the Ligand Pharmaceuticals Incorporated company belong to?

The Ligand Pharmaceuticals Incorporated sector is Healthcare.

Ligand Pharmaceuticals Incorporated LGND included in indexes

Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
Name Name Price Price 24h%
7d chart
24h% & 7d
VOL Volume 24h low 24h high Volume
{{ item.name }} {{ item.symbol }} {{ item.price }} {{ item.price_usd }}
{{ item.change_pct }}
{{ item.volume }} {{ item.volume_usd }} {{ item.low }} {{ item.low_usd }} {{ item.high }} {{ item.high_usd }} {{ item.components_count }} {{ item.volume }} {{ item.volume_usd }}
NASDAQ Composite IXIC 16399.52 USD
+0.51
4.29B USD 16279.17 USD 16431.82 USD 4.29B USD
NASDAQ HealthCare IXHC 1012.23 USD
+1.45
999.52 USD 1012.31 USD
NASDAQ Composite Total Return I XCMP 19928.44 USD
+0.52
19782.2 USD 19967.69 USD
Nasdaq US 700 Small Cap Value I NQUS700SCV 2132.01 USD
+2.67
2089.99 USD 2132.16 USD
NASDAQ Global Market Composite NQGM 2272.08 USD
+1.99
2229.63 USD 2272.08 USD
Stlmt ID NASDAQ Biotechnology NBX 4604.4 USD
-2.98
4555.41 USD 4917.8 USD
Nasdaq US CapEx Achievers Index CAPEXA 2846.58 USD
+1
2826.56 USD 2847.17 USD
NASDAQ Biotechnology Total Retu XNBI 4770.92 USD
+1.53
4699.51 USD 4771.32 USD
Nasdaq US 700 Small Cap Value N NQUS700SCVN 2367.56 USD
+2.72
2320.92 USD 2367.72 USD
Nasdaq US 700 Small Cap Index NQUS700SC 2171.4 USD
+2.38
2136.52 USD 2171.53 USD
Nasdaq AlphaDEX Multi Cap Growt NQDXUSMLTCG 2654.31 USD
+0.94
2630.31 USD 2654.61 USD
NASDAQ Biotechnology NBI 4446.02 USD
+1.53
4379.48 USD 4446.39 USD